

Product Datasheet


Orismilast

Catalog No. **BP-01457** · CAS **1353546-86-7** · Form **free base** · Physical state **other** · Color **white to off-white** · Version **1.0** · Revision **2026-09-04**

FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Phosphodiesterase (PDE)	Research area Inflammation/Immunology
--	---

Molecular formula	C₁₉H₁₅Cl₂F₂NO₇S
Molecular weight	510.2930



DESCRIPTION

Orismilast (LEO-32731) is an orally active and selective PDE4 inhibitor used for the research of inflammatory diseases. Orismilast demonstrates potent inhibition of PDE4B and PDE4D subtype splice variants .

BIOLOGICAL ACTIVITY

In Vitro

Orismilast inhibits tumour necrosis factor α (TNF α), and the secretion of T-helper (Th)1 (TNF α and IFN γ), Th17 (IL-22 and IL-23), and Th2 (IL-4, IL-5, and IL-13) related cytokines in PBMC.

In Vivo

Orismilast (10 and 30mg/kg) significantly reduces ear thickness and inflammation markers ($p < 0.0001$, respectively).

SOLUBILITY

soluble in DMSO

REFERENCES

- [1]. Nielsen, et al. Preparation of benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors. WO2011160632A1.
- [2]. Jonathan I Silverberg, et al. Pharmacology of orismilast, a potent and selective PDE4 inhibitor. J Eur Acad Dermatol Venereol. 2023 Apr;37(4):721-729.